ECSP099675A - Compuestos heterocíclicos, composición y métodos de uso - Google Patents

Compuestos heterocíclicos, composición y métodos de uso

Info

Publication number
ECSP099675A
ECSP099675A EC2009009675A ECSP099675A ECSP099675A EC SP099675 A ECSP099675 A EC SP099675A EC 2009009675 A EC2009009675 A EC 2009009675A EC SP099675 A ECSP099675 A EC SP099675A EC SP099675 A ECSP099675 A EC SP099675A
Authority
EC
Ecuador
Prior art keywords
composition
methods
heterocyclic compounds
revealed
disorders
Prior art date
Application number
EC2009009675A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth G Carson
David J Augeri
Jeffrey Bagdanoff
Theodore C Jessop
James Tarver
Simon D P Baugh
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of ECSP099675A publication Critical patent/ECSP099675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EC2009009675A 2007-03-01 2009-10-02 Compuestos heterocíclicos, composición y métodos de uso ECSP099675A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90435707P 2007-03-01 2007-03-01

Publications (1)

Publication Number Publication Date
ECSP099675A true ECSP099675A (es) 2009-11-30

Family

ID=39577881

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009675A ECSP099675A (es) 2007-03-01 2009-10-02 Compuestos heterocíclicos, composición y métodos de uso

Country Status (23)

Country Link
US (3) US7598280B2 (enExample)
EP (1) EP2125788B9 (enExample)
JP (1) JP5610772B2 (enExample)
KR (1) KR20090117763A (enExample)
AR (1) AR065509A1 (enExample)
AT (1) ATE504585T1 (enExample)
AU (1) AU2008223210B2 (enExample)
BR (1) BRPI0808172A2 (enExample)
CA (1) CA2679101C (enExample)
CO (1) CO6220950A2 (enExample)
DE (1) DE602008006045D1 (enExample)
DK (1) DK2125788T3 (enExample)
EA (1) EA016495B1 (enExample)
EC (1) ECSP099675A (enExample)
ES (1) ES2364116T3 (enExample)
IL (1) IL200387A (enExample)
MX (1) MX2009009190A (enExample)
NZ (1) NZ578974A (enExample)
PL (1) PL2125788T3 (enExample)
PT (1) PT2125788E (enExample)
TW (1) TW200848029A (enExample)
WO (1) WO2008109314A1 (enExample)
ZA (1) ZA200905671B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3322772B2 (ja) 1995-05-22 2002-09-09 日本エム・ケー・エス株式会社 制御弁
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
UY31900A (es) * 2008-06-18 2010-01-29 Lexicon Pharmaceuticals Inc Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso.
AU2009282907A1 (en) * 2008-08-22 2010-02-25 Lexicon Pharmaceuticals, Inc. Combinations comprising bicyclic S1P lyase inhibitors
AR074061A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica
JP5645318B2 (ja) 2010-02-18 2014-12-24 第一三共株式会社 イミダゾール誘導体
JP5757635B2 (ja) 2010-06-28 2015-07-29 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
EP2727926A4 (en) 2011-06-28 2015-03-04 Daiichi Sankyo Co Ltd PHOSPHORIC ESTER DERIVATIVE
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
US20230121797A1 (en) * 2020-03-27 2023-04-20 Ac Bioscience Sa A combination of flavonoids and sphingosine 1 phosphate lyase inhibitors for the treatment of lung inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
AU2881797A (en) * 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
CN1834095B (zh) * 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
EP1898928A2 (en) * 2005-06-28 2008-03-19 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TWI412362B (zh) 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式

Also Published As

Publication number Publication date
DE602008006045D1 (de) 2011-05-19
TW200848029A (en) 2008-12-16
KR20090117763A (ko) 2009-11-12
EA016495B1 (ru) 2012-05-30
BRPI0808172A2 (pt) 2014-11-04
AU2008223210B2 (en) 2013-08-22
US7825142B2 (en) 2010-11-02
US20110082178A1 (en) 2011-04-07
ATE504585T1 (de) 2011-04-15
IL200387A (en) 2013-10-31
ZA200905671B (en) 2010-10-27
WO2008109314A1 (en) 2008-09-12
ES2364116T3 (es) 2011-08-25
EP2125788A1 (en) 2009-12-02
JP2010520214A (ja) 2010-06-10
CO6220950A2 (es) 2010-11-19
US20090312375A1 (en) 2009-12-17
US7598280B2 (en) 2009-10-06
PL2125788T3 (pl) 2011-09-30
AR065509A1 (es) 2009-06-10
DK2125788T3 (da) 2011-07-11
AU2008223210A1 (en) 2008-09-12
EA200970818A1 (ru) 2010-02-26
IL200387A0 (en) 2010-04-29
CA2679101A1 (en) 2008-09-12
US20090030050A1 (en) 2009-01-29
MX2009009190A (es) 2009-09-04
EP2125788B1 (en) 2011-04-06
JP5610772B2 (ja) 2014-10-22
CA2679101C (en) 2015-11-24
EP2125788B9 (en) 2011-07-20
NZ578974A (en) 2011-11-25
PT2125788E (pt) 2011-07-05

Similar Documents

Publication Publication Date Title
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
ECSP088692A (es) Compuestos basados en imidazol, composiciones que comprenden a los mismos y métodos de su uso
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
HN2009001178A (es) 4-fenilo-piano-3,5-diones, 4 fenilo- thiopirano-3,5-diones y ciclohexanetriones como herbicidas novedosos
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
ES2525801T8 (es) Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
ME01532B (me) Jedinjenja
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
CL2012000752A1 (es) Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios.
CR10427A (es) Quinazolinas para la inhibicion de pdk1
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio